• Qiang Ji, Qing Wang, Wenping Pan, Yanfeng Hou, Xiuhua Wang, Lin Bian, and Zhankui Wang.
• First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
• Medicine (Baltimore). 2022 Aug 19; 101 (33): e30065e30065.

RationaleSAPHO syndrome is a rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Treatment strategies are not standardized. Palmoplantar pustulosis (PPP) is the most common rash in patients with SAPHO syndrome.Patient ConcernsA 24-year-old Chinese woman with no relevant medical or familial history had a 1-year history of cutaneous lesions with PPP and pain in the sternoclavicular joint.DiagnosisBased on the diagnostic criteria for SAPHO syndrome proposed by Nguyen et al in 2012, we diagnosed SAPHO syndrome with severe PPP as the predominant manifestation.InterventionsDue to the limited therapeutic efficacy of methotrexate and cyclosporin, we started therapy with subcutaneous secukinumab 150 mg weekly for the first month, then 150 mg monthly thereafter.OutcomesAfter 4 weeks of secukinumab administration, the patient showed significant remission of pustular skin lesions, with almost no joint pain and no adverse reaction. Complete remission of skin symptoms was achieved after 3 months. Joint pain and adverse events have not reoccurred in follow-up thus far.ConclusionsIn patients with SAPHO syndrome, we recommend personalized treatment, which may have excellent therapeutic efficacy in those with PPP or severe skin symptoms. Although data related to the use of IL-17 blockers for SAPHO syndrome are very limited, secukinumab provides a novel therapeutic option, especially for patients with PPP and severe skin lesions. Further prospective studies are needed to support our findings.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

21 keywords...

hide…